LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 102 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q1 2021. The put-call ratio across all filers is 2.57 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $197,400 | -6.0% | 140,000 | 0.0% | 0.05% | -14.3% |
| Q1 2023 | $210,000 | +28.2% | 140,000 | 0.0% | 0.06% | +37.0% |
| Q4 2022 | $163,800 | +3.7% | 140,000 | 0.0% | 0.05% | +9.5% |
| Q3 2022 | $158,000 | -28.5% | 140,000 | 0.0% | 0.04% | -30.0% |
| Q2 2022 | $221,000 | +2.3% | 140,000 | 0.0% | 0.06% | +7.1% |
| Q1 2022 | $216,000 | +10.2% | 140,000 | +75.0% | 0.06% | +14.3% |
| Q4 2021 | $196,000 | +10.7% | 80,000 | +6.1% | 0.05% | +16.7% |
| Q1 2021 | $177,000 | +25.5% | 75,400 | -5.8% | 0.04% | 0.0% |
| Q4 2020 | $141,000 | +58.4% | 80,000 | -15.8% | 0.04% | +44.8% |
| Q3 2020 | $89,000 | +7.2% | 95,000 | 0.0% | 0.03% | +20.8% |
| Q2 2020 | $83,000 | +5.1% | 95,000 | 0.0% | 0.02% | -27.3% |
| Q1 2020 | $79,000 | -7.1% | 95,000 | 0.0% | 0.03% | +13.8% |
| Q4 2019 | $85,000 | -8.6% | 95,000 | 0.0% | 0.03% | -17.1% |
| Q3 2019 | $93,000 | – | 95,000 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BROADWOOD CAPITAL INC | 34,935,485 | $41,223,872 | 3.66% |
| Raffles Associates | 1,587,739 | $1,873,532 | 2.48% |
| Defender Capital, LLC. | 5,184,510 | $6,117,722 | 2.22% |
| Prescott General Partners LLC | 1,851,851 | $2,185,184 | 0.14% |
| DCF Advisers, LLC | 82,751 | $97,646 | 0.05% |
| Beirne Wealth Consulting Services, LLC | 45,000 | $63,450 | 0.05% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 781,766 | $922,484 | 0.02% |
| Fort Sheridan Advisors LLC | 83,931 | $99,039 | 0.02% |
| MAI Capital Management | 954,688 | $1,126,532 | 0.02% |
| Piscataqua Savings Bank | 12,499 | $14,623 | 0.01% |